NCT00461851View on ClinicalTrials.gov

Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Bladder Cancer
Interventions
DRUG

Gemcitabine

Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.

DRUG

Carboplatin

Carboplatin will be given on day 1 to an AUC of 5.

DRUG

Sorafenib

Sorafenib will be administered orally daily on days 2-19 at 400 mg bid

Trial Locations (1)

06520

Yale University, Comprehensive Cancer Center, New Haven

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Yale University

OTHER